Cellfactory

Útbaigazítási információk Weboldal

Cellfactory Expert services transferring discoveries to GLP/GMP Compliant Products

A Cellfactory Kft. a Széchenyi Terv Plusz program keretében a „KKV-k innovációs képességének támogatása” c. felhívásra b...
24/07/2026

A Cellfactory Kft. a Széchenyi Terv Plusz program keretében a „KKV-k innovációs képességének támogatása” c. felhívásra benyújtott, GINOP_PLUSZ-2.1.3-24-2024-00349 azonosítószámmal nyilvántartott „A Cellfactory Kft. folyamatinnovációs fejlesztése” c. kérelme 49,23 millió forint vissza nem térítendő támogatásban részesült.

A projekt az Európai Unió támogatásával, a magyar állam társfinanszírozásával valósult meg.

A projekt keretében a CellFactory Kft. termelés-optimalizálási és marketingfolyamat-innovációs fejlesztéseket valósított meg. Korszerűsítette sejttenyésztési folyamatait, új technológiai megoldásokat vezetett be, valamint egy nagykapacitású CO₂-inkubátort és egy többfunkciós mikrolemez-olvasót szerzett be a termelési folyamatok hatékonyabb működése érdekében. A fejlesztések eredményeként hatékonyabbá vált a sejttenyészetek előállítása, csökkent az erőforrás-felhasználás, és lehetővé vált a tenyésztett sejtek hatékonyságának korszerű vizsgálata. Emellett a vállalat fejlesztette online marketing- és ügyfélelérési tevékenységét is, amely erősíti piaci jelenlétét.



Főbb információk a projektről:

Projekt megvalósítási időtartama: 2025.05.15. – 2026.06.30.

Projekt helyszíne: 6726 Szeged, Temesvári krt. 58-60.

Projekt összköltsége: 70 323 075 Ft

Támogatás összege: 49 226 152 Ft

Támogatás mértéke: 69,99%

A projektről bővebb információt a https://cellfactory.eu/szeczenyi-terv-plus/ oldalon olvashatnak.

30/06/2026

The most important part of our day happens before we even touch a pipette.

The "gowning" process is a choreographed ritual. Hairnets, hoods, coveralls, boots, and double-gloves. It takes time, it takes discipline, and it’s the first line of defence for our clients' products.

It might look like a lot of effort, but in the world of GMP, discipline is the foundation of quality.

30/06/2026

There's a quiet, underrated art to doing something exactly the same way, every single time.

In cell manufacturing, that consistency is the whole point, and it takes a particular kind of person to deliver it: someone who finds reassurance, not boredom, in a well-written protocol followed to the letter. We value that temperament enormously, because it's what turns a good process on paper into a dependable one, batch after batch.

Reliability is rarely glamorous and almost never celebrated. It's also essential to everything we promise.

Choosing a manufacturing partner is a high-stakes decision, so ask the hard, slightly awkward questions early rather tha...
30/06/2026

Choosing a manufacturing partner is a high-stakes decision, so ask the hard, slightly awkward questions early rather than late.

How do you handle deviations when they happen? What's your real track record with cell lines like mine? Who, specifically, would run my project day to day, and how often would I hear from them? The honest answers reveal far more about how a facility works than any glossy brochure.

We'd encourage you to ask us every one of them, and we'll always answer plainly.

The road from a promising bench result to an approved therapy is long, uncertain, and demanding, and very few teams shou...
30/06/2026

The road from a promising bench result to an approved therapy is long, uncertain, and demanding, and very few teams should walk it alone.

We exist to share that journey: the facilities, the regulatory experience and the hard-won manufacturing discipline to help your science reach a finish line that's usually further off than it looks. The breakthrough science is yours. The path from there to the patient is something we can carry together.

Wherever you are on that path, we'd like to help you take the next step.

30/06/2026

Two words are shaping the future of cell therapy: allogeneic and autologous.

Autologous therapies use a patient's own cells, which makes them deeply personal but also complex and hard to scale. Allogeneic therapies use screened donor cells to treat many people from one source, promising far broader reach while raising fresh questions about manufacturing, matching and consistency. Both will help define the decade ahead, and neither is going away.

We're building the flexibility to support either path, since the field itself hasn't yet decided.

You've spent years perfecting your cell line. You've proven the concept. Now it's time to get it to the people who need ...
30/06/2026

You've spent years perfecting your cell line. You've proven the concept. Now it's time to get it to the people who need it.

We don't want to be just another vendor. We want to be the extension of your lab that helps you cross the finish line.

Our cleanrooms are ready and our scientists are on hand. Let's build the future of biotech together.

Contact: [email protected]

Not all cells grow the same way, and that one distinction shapes everything downstream.Adherent cells need a surface to ...
30/06/2026

Not all cells grow the same way, and that one distinction shapes everything downstream.

Adherent cells need a surface to attach to, which makes scaling them up a real engineering challenge. Suspension cells float freely in their media and are usually much easier to grow at scale. Choosing between the two, or adapting a line from one to the other, is one of the biggest calls you make early in development, and a hard one to reverse later.

Understand your cell line's preferences from the start, and you'll avoid a lot of expensive surprises down the line.

For many startups, the temptation to keep manufacturing "in-house" is strong. But the hidden costs—facility maintenance,...
30/06/2026

For many startups, the temptation to keep manufacturing "in-house" is strong. But the hidden costs—facility maintenance, regulatory filings, and QA staffing—can quickly drain a R&D budget.

Outsourcing to a specialised CDMO like Cellfactory doesn't just offload the work; it offloads the risk. Use our infrastructure to keep your capital focused on the science.

30/06/2026

We'd like to introduce you to CellFactory. 🔬
We're a contract development and manufacturing organisation (CDMO) working to advance stem cell treatments, based in our GMP-compliant facility in Szeged, Hungary.
Our team brings together scientists and quality-assurance specialists who really know cell therapy design and the regulatory standards that come with it. It's careful, detailed work, and we love what it makes possible.
Come and see how we do it.

Cím

Szeged, Temesvári Krt. 58
Szeged
6726

Weboldal

Értesítések

Ha szeretnél elsőként tudomást szerezni Cellfactory új bejegyzéseiről és akcióiról, kérjük, engedélyezd, hogy e-mailen keresztül értesítsünk. E-mail címed máshol nem kerül felhasználásra, valamint bármikor leiratkozhatsz levelezési listánkról.

Parancsikonok

Megosztás

Kategória